AstraZeneca: Enhertu Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
September 13, 2023
September 13, 2023
WILMINGTON, Delaware, Sept. 13 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Sept. 11, 2023:
* * *
AstraZeneca and Daiichi Sankyo's ENHERTU showed objective response rates of 49% and 56% with 5.4mg/kg and 6.4mg/kg doses respectively in primary analysis
ENHERTU provided a median progression-free survival of 9.9 months at 5.4mg/kg dose and 15.4 months at 6.4mg/kg dose with a median duration of response of 16.8 mont . . .
* * *
AstraZeneca and Daiichi Sankyo's ENHERTU showed objective response rates of 49% and 56% with 5.4mg/kg and 6.4mg/kg doses respectively in primary analysis
ENHERTU provided a median progression-free survival of 9.9 months at 5.4mg/kg dose and 15.4 months at 6.4mg/kg dose with a median duration of response of 16.8 mont . . .